Clinical Trials Logo

Recurrent Epithelial Ovarian Cancer clinical trials

View clinical trials related to Recurrent Epithelial Ovarian Cancer.

Filter by:
  • None
  • Page 1

NCT ID: NCT02785250 Recruiting - Clinical trials for Recurrent Fallopian Tube Cancer

Study of DPX-Survivac Vaccine Therapy and Epacadostat in Patients With Recurrent Ovarian Cancer

Start date: April 2016
Phase: Phase 1
Study type: Interventional

Immunotherapeutic survivin vaccine DPX-Survivac, low dose oral cyclophosphamide, and IDO1 inhibitor epacadostat will be tested together for the first time in patients with recurrent ovarian, fallopian tube, or peritoneal cancer to determine the safety and potential immune-modulating activity of the combination of these agents.

NCT ID: NCT01853644 Recruiting - Clinical trials for Recurrent Fallopian Tube Cancer

Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer

TIVO
Start date: May 2013
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well tivozanib works in treating patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer. Tivozanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT01815528 Completed - Clinical trials for Recurrent Epithelial Ovarian Cancer

Feasibility and Clinical Activity of Initial Intraperitoneal Catumaxomab Followed by Chemotherapy in Patients With Recurrent Ovarian Cancer

Start date: March 2013
Phase: Phase 2
Study type: Interventional

Single -arm, multicenter phase-II trial for catumaxomab and chemotherapy in patients with recurrent ovarian cancer to investigate the feasibility and clinical activity of initial intraperitoneal catumaxomab followed by chemotherapy regimes.

NCT ID: NCT01472783 Completed - Clinical trials for Recurrent, Epithelial Ovarian Cancer

Veliparib Monotherapy for Relapsed Ovarian Cancer With BRCA Mutation

Veli-BRCA
Start date: November 2011
Phase: Phase 1/Phase 2
Study type: Interventional

The main purpose of this study is to investigate the effect of veliparib in ovarian cancer patients with known BRCA 1/2 mutations who do no longer respond to conventional chemotherapy.

NCT ID: NCT01334047 Terminated - Clinical trials for Recurrent Epithelial Ovarian Cancer

Trial of Vaccine Therapy in Recurrent Platinum Sensitive Ovarian Cancer Patients

Start date: April 2011
Phase: Phase 1/Phase 2
Study type: Interventional

In this study the investigators will include patients with relapsed epithelial ovarian cancer. In spite of increased rates of complete response to initial chemotherapy, most patients with advanced ovarian cancer relapse and succumb to progressive disease. Immunotherapy may have potential for consolidation therapy. Dendritic cell vaccine is well toleranted in previous studies, with minor side effects and no serious adverse events registrated In this study, patients will receive DC-vaccine therapy after response to platinum treatment at relapse. The investigtors include patients in good clinical condition with no severe symptoms of the disease. If patients relapse during vaccine treatment, they will be discontinued from the study. The investigators have included hTERT- and survivin mRNA in addition to amplified cancer stem cell mRNA in the vaccine.